Answers are grounded in this paper and cite their sources.
Dear Editor, A phenotypic range of exclusively cutaneous adverse events following immunization (AEFI) with COVID‐19 vaccines has been reported. Currently, there is no formal consensus on advice given to affected individuals pertaining to their subsequent COVID‐19 vaccines, which is increasingly pertinent as countries such as the UK launch a further booster phase of the COVID‐19 mass vaccination programme, owing to concerns over waning immunity from initial vaccinations. We describe the phenotypic spectrum of rare but serious cutaneous AEFI and explore the evidence underlying AEFI, based on the literature and our multicentre case series. We used the World Health Organization (WHO) definition for serious adverse event as ‘any untoward medical occurrence that at any dose: results in death, is life‐threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity’.1 This multicentre case series (Table S12–14) comprised 21 patients (10 men, 11 women; aged 21–83 years) with ethnicities reported as White British (n = 16), South Asian (n = 3), Black (n = 1) and Chinese (n = 1), who presented with serious cutaneous‐only AEFI during the period February–August 2021.
No takes yet. Share an insight, caveat, or question.
BALOGUN et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: